Johan Järte
Plus aucun poste en cours
Profil
Johan Järte was the Chief Executive Officer at SentoClone AB.
Anciens postes connus de Johan Järte
Sociétés | Poste | Fin |
---|---|---|
SentoClone AB
SentoClone AB Miscellaneous Commercial ServicesCommercial Services SentoClone AB is a Swedish scientific research company developing SentoClone® - a patented method where the immune defense system is activated and strengthened to combat cancer. SentoClone is registered with the European Medicines Ageny, EMEA, as an SME (small and medium sized enterprises). SentoClone AB is a member of the IML, The Swedish Association for small and medium-sized companies active in R&D. SentoClone AB is owned by a number of venture capital firms, among them Stena Adactum AB, Sahltech i Göteborg AB and T-bolaget AB, together with founders Ola Winqvist and Magnus Thörn. | President | 31/12/2012 |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 1 |
---|---|
SentoClone AB
SentoClone AB Miscellaneous Commercial ServicesCommercial Services SentoClone AB is a Swedish scientific research company developing SentoClone® - a patented method where the immune defense system is activated and strengthened to combat cancer. SentoClone is registered with the European Medicines Ageny, EMEA, as an SME (small and medium sized enterprises). SentoClone AB is a member of the IML, The Swedish Association for small and medium-sized companies active in R&D. SentoClone AB is owned by a number of venture capital firms, among them Stena Adactum AB, Sahltech i Göteborg AB and T-bolaget AB, together with founders Ola Winqvist and Magnus Thörn. | Commercial Services |